Pregabalin Now Under Strict H1 Rules to Prevent Drug Abuse
The Central government has introduced tighter controls on Pregabalin by bringing it under the stringent Schedule H1 category. This regulatory change was prompted by growing evidence of the drug being...
The Central government has introduced tighter controls on Pregabalin by bringing it under the stringent Schedule H1 category. This regulatory change was prompted by growing evidence of the drug being misused for its sedative and euphoric effects rather than its intended medical purposes. The Health Ministry's notification, published in the official gazette, marks a clear shift from the previous Schedule H classification to more rigorous oversight. Under the new framework, Pregabalin can only be dispensed with a valid prescription from a registered medical practitioner. Retail sellers are mandated to maintain separate registers documenting every sale and prescription details. The packaging must also carry the mandatory Schedule H1 warning, clearly stating that the drug should not be taken without medical advice and cannot be sold without a prescription. The ministry highlighted recent cases of illegal stock accumulation and unauthorized sales that have been reported from various regions. These incidents have raised serious public health concerns, prompting the need for stronger regulatory intervention. The move is designed to improve prescription tracking, prevent unauthorized access, and reduce the chances of the drug entering the black market. By enforcing these measures, the government aims to protect citizens from the harmful effects of drug misuse while ensuring that legitimate patients continue to receive necessary treatment. All stakeholders in the pharmaceutical supply chain have been advised to strictly follow the updated guidelines to avoid penalties and contribute to a safer healthcare environment.